PCMC
STOK icon

Planning Capital Management Corporation’s Stoke Therapeutics STOK Stock Holding History

Planning Capital Management Corporation’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$861 Hold
70
– – ﹤0.01% 637
2024
Q2 		$946 Buy
+70
New +$945 ﹤0.01% 591

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Planning Capital Management Corporation's STOK Position: Q3 2024 in Review

Planning Capital Management Corporation held its Stoke Therapeutics (STOK) position steady in Q3 2024 at 70 shares worth $861. The position accounts for ﹤0.01% of the portfolio, ranked #637.

Planning Capital Management Corporation first reported a position in STOK in Q2 2024 and has held it in 2 quarters since. The position peaked at $946 in Q2 2024. 118 funds tracked by Wall St. Rank hold STOK as of Q3 2024.

  • Planning Capital Management Corporation held 70 shares of Stoke Therapeutics worth $861 as of Q3 2024.
  • Planning Capital Management Corporation left its Stoke Therapeutics share count unchanged in Q3 2024.
  • Stoke Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #637 holding.
  • Planning Capital Management Corporation first reported a position in Stoke Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Planning Capital Management Corporation's Stoke Therapeutics position peaked at $946 in Q2 2024.
  • 118 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.